

Supporting Information


Proteasome Selectivity Towards Michael Acceptor Containing Oligopeptide-based Inhibitors

**Wouter A. van der Linden, Paul P. Geurink, Chris Oskam, Gijsbert A. van der Marel, Bogdan I.
Florea, Herman S. Overkleeft***

**Leiden Institute of Chemistry and Netherlands Proteomics Centre,
P.O. Box 9502, 2300 RA, Leiden, The Netherlands E-mail:
h.s.overkleeft@chem.leidenuniv.nl; Fax: +31-71-5274307;
Tel: +31-71-5274342*

General

All reagents were commercial grade and were used as received unless indicated otherwise. Toluene (Tol.) (purum), ethyl acetate (EtOAc) (puriss.), and light petroleum ether (PetEt) (puriss.) were obtained from Riedel-de Haën and were distilled prior to use. Dichloromethane (DCM), dimethyl formamide (DMF), and dioxane (Biosolve) were stored on 4 Å molecular sieves. Tetrahydrofuran (THF) (Biosolve) was distilled from LiAlH₄ prior to use. Reactions were conducted under an argon atmosphere. Reactions were monitored by TLC analysis by using DC-fertigfolien (Schleicher & Schuell, F1500, LS254) with detection by UV absorption (254 nm), spraying with 20% H₂SO₄ in ethanol, followed by charring at ~150°C; by spraying with a solution of (NH₄)₆Mo₇O₂₄C₄H₂O (25 g/L) and (NH₄)₄Ce(SO₄)₄C₂H₂O (10 g/L) in 10% sulfuric acid, followed by charring at ~150°C; or by spraying with an aqueous solution of KMnO₄ (7%) and KOH (2%). Column chromatography was performed on Screening devices (0.040–0.063 nm). LC/MS analysis was performed on a LCQ Advantage Max (Thermo Finnigan) equipped with an Gemini C18 column (Phenomenex). HRMS were recorded on a LTQ Orbitrap (Thermo Finnigan). ¹H- and ¹³C-APT-NMR spectra were recorded on a Jeol JNM-FX-200 (200/50), Bruker DPX-300 (300/75 MHz), Bruker AV-400 (400/100 MHz) equipped with a pulsed field gradient accessory or a Bruker AV-500 (500/125 MHz). Chemical shifts are given in ppm (δ) relative to tetramethylsilane as an internal standard. Coupling constants are given in Hz. All presented ¹³C-APT spectra are proton decoupled. IR spectra were recorded on a Shimadzu FTIR-8300 spectrometer. Optical rotations were measured on a Propol automatic polarimeter (sodium D line, λ = 589 nm).



(S,E)-4-Boc-amino-6-methylhept-2-enenitrile (13). Diethyl cyanomethylphosphonate (1.39 g, 7.88 mmol, 1.5 equiv.) was dissolved in 30 mL THF at 0°C. NaH (60% disp. in mineral oil, 0.315 g, 7.88 mmol, 1.5 equiv.) was added and the mixture was stirred for 30 minutes. Boc-leucinal **2** (1.11 g, 5.16 mmol, 1 equiv.) in THF was added, and the mixture was stirred o/n. EA was added, and the mixture was extracted with 1M HCl (2x) and brine. The organic layer was dried with MgSO₄ and concentrated. Column chromatography (EA:PE (10-25%)) yielded the title compound (0.52 g, 2.18 mmol, 42%). ¹H NMR (200 MHz, CDCl₃): δ ppm 6.61 (dd, *J*₁ = 16.26 Hz, *J*₂ = 5.12 Hz, 1H), 5.49 (dd, *J*₁ = 16.06 Hz, *J*₂ = 1.46 Hz, 1H), 4.45–4.20 (m, 2H), 1.80–1.35 (m, 12H), 0.94 (d, *J* = 6.58 Hz, 6H). ¹³C NMR (50.1 MHz, CDCl₃): δ ppm 155.44, 154.80, 116.71, 98.53, 79.18, 50.1, 42.37, 27.85, 24.22, 22.82, 21.41.


Boc-leucine vinyl diethylphosphonate (23). Tetraethyl methylenediphosphonate (0.9 g, 3.12 mmol, 1.5 equiv.) was dissolved in 10 mL THF at 0°C. NaH (60% disp in mineral oil, 125 mg, 3.12 mmol, 1.5 equiv.) was added, and the mixture was stirred for 30 minutes at 0°C. Boc-leucinal **2** (448 mg, 2.08 mmol, 1 equiv.) in THF was added and the resulting mixture was stirred for 3h. 1M HCl and EA were added, and the layers were separated. The organic layer was washed with 1M HCl and brine and was dried with MgSO₄ and concentrated. Column chromatography yielded the title compound (596 mg, 1.71 mmol, 82%). ¹H NMR (200 MHz, CDCl₃): δ ppm 6.66 (ddd, *J*₁ = 21.91 Hz, *J*₂ = 17.17 Hz, *J*₃ = 4.76 Hz, 1H), 5.77 (ddd, *J*₁ = 17.16 Hz, *J*₂ = 3.66 Hz, *J*₃ = 1.46 Hz, 1H), 4.45–4.15 (m, 2H), 4.07 (p, *J* = 7.68 Hz, 4H), 1.78–1.50 (m, 1H), 1.44 (s, 9H), 1.40–1.25 (m, 8H), 0.93 (d, *J* = 6.56 Hz, 6H). ¹³C NMR (50.1 MHz, CDCl₃): δ ppm 154.70, 153.08, 152.99, 116.85, 113.13, 78.13, 77.64, 77.00, 76.35,

60.88, 60.77, 50.63, 50.22, 42.53, 27.61, 23.97, 22.03, 21.30, 21.24, 15.49. α_D^{20} -14.5° (c = 1.00, CHCl₃).

(S,E)-1-(diphenylphosphinoxide)-3-(Boc-amino)-5-methyl-1-hexene (24). Diethyl methylphosphonate (0.96 g, 6.32 mmol, 1 equiv.) was dissolved in THF and cooled to -78°C. LiHMDS (12.64 mL 1M sln in THF/EtPh, 2 equiv.) was added and the solution was stirred for 15 min. Chlorodiphenylphosphinoxide (1.5 g, 6.32 mmol, 1 equiv.) was added and the solution was stirred for 1h at -40°C. Boc-leucinal **2** (1.48 g, 6.3 mmol, 1 equiv.) in THF was added dropwise, and the mixture was stirred for 3h at -40°C. The reaction was quenched with H₂O, and the resulting mixture was extracted with EA (3x). The combined organic layers were dried with Na₂SO₄ and concentrated. Flash column chromatography (EA:PE 40-80%, 2x) yielded the title compound (184 mg, 0.29 mmol, 5% isolated yield). ¹H NMR (400 MHz, CDCl₃): δ ppm 7.78-7.36 (m, 10H), 6.79-6.51 (m, 1H), 6.45-6.32 (m, 1H), 4.98-4.71 (m, 1H), 4.42-4.20 (m, 1H), 1.88-1.13 (m, 12H), 0.98-0.83 (m, 6H). ¹³C NMR (100 MHz, CDCl₃): δ ppm 155.08, 152.01, 133.35, 133.11, 132.30, 132.08, 131.60, 131.21, 131.12, 128.41, 128.29, 121.55, 120.54, 79.32, 51.58, 51.41, 43.19, 28.16, 24.56, 22.61, 21.92.

Diethyl 1-adamantylsulfonylmethylphosphonate (25). 1-adamantylthiol (1.77 g, 10 mmol, 1 equiv.) was dissolved in 50 mL THF at 0°C. NaH (0.42 g 60% disp. in min. oil, 10.5 mmol, 1.05 equiv.) was added, and the mixture was stirred for 1h. diethyl iodomethylphosphonate (2.78 g, 10 mmol, 1 equiv.) in THF was added, and the mixture was stirred for 1.5 h. The reaction was quenched with 1M HCl, and the mixture was extracted with DCM (2x). The organic layer was dried with MgSO₄ and concentrated. The residue was dissolved in 1,4-dioxane and cooled to 0°C. Peroxyacetic acid (8.4 mL 32% in AcOH (w/w), 40 mmol, 4 equiv.) was added and the mixture was stirred for 2h. Sat. aq. NaHCO₃ was added, and the mixture was extracted with EA (2x). The organic layer was dried with MgSO₄ and concentrated. The residue was recrystallised from EA:PE to yield the title compound (2.79 g, 7.95 mmol, 79%). ¹H NMR (400 MHz, CDCl₃): δ ppm 4.31-4.23 (m, 4H), 3.48 (d, *J* = 18.66 Hz, 2H), 2.21 (s, 3H), 2.04 (d, *J* = 2.31 Hz, 6H), 1.80-1.66 (m, 6H), 1.38 (t, *J* = 7.07 Hz, 6H). ¹³C NMR (100 MHz, CDCl₃): δ ppm 63.61, 63.54, 42.81, 41.46, 35.60, 34.65, 28.12, 16.29, 16.22.

Boc-leucinyl vinyl-1-adamantylsulfone (26). Diethyl 1-adamantylsulfonylmethylphosphonate **25** (1.9 g, 5.4 mmol, 1.1 equiv.) was dissolved in 50 mL THF at 0°C. KOtBu (607 mg, 5.4 mmol, 1.1 equiv.) was added and the mixture was stirred for 30 min. Boc-leucinal (1.06 g, 4.92 mmol, 1 equiv.) in THF was added and the mixture was stirred at 0°C for 1h. Sat. aq. NH₄Cl was added and the mixture was extracted with EA (2x). The organic layer was dried with MgSO₄ and concentrated. Column chromatography (EA:PE (5-30%)) and recrystallisation from DCM:PE yielded the title compound (1.22 g, 3.06 mmol, 62%). ¹H NMR (400 MHz, CDCl₃): δ ppm 6.69 (dd, *J* = 15.04, 5.33 Hz, 1H), 6.33 (d, *J* = 15.11 Hz, 1H), 5.17 (d, *J* = 7.61 Hz, 1H), 4.40-4.29 (m, 1H), 2.14 (s, 3H), 2.01-1.90 (m, 6H), 1.80-1.62 (m, 7H), 1.47-1.41 (m, 11H), 0.96-0.91 (m, 6H). ¹³C NMR (100 MHz, CDCl₃): δ ppm 154.77, 150.76, 122.70, 79.16, 59.40, 49.75, 42.38, 35.45, 34.22, 27.97, 27.75, 24.35, 22.34, 21.73.



AdaAhxOMe (27). To a solution of methyl 6-aminohexanoate HCl salt (0.78 g, 4.30 mmol) and 1-adamantaneacetic acid (0.94 g, 4.73 mmol) in DCM (25 mL) were added HCTU (2.0 g, 4.94 mmol) and DiPEA (2.31 mL, 14 mmol). The mixture was stirred for 3 hours, after which EtOAc (100 mL)

was added followed by extraction of the mixture with 1M HCl (2x), saturated NaHCO₃ (2x) and brine. Drying over MgSO₄ and concentration of the mixture resulted in crude product, which was further purified by column chromatography (EA:PE (10-100%)). The product (yield: 1.38 g, 4.30 mmol, quant.) was obtained as a colorless solid. ¹H NMR (400 MHz, CDCl₃): δ ppm 5.60-5.53 (m, 1H), 3.67 (s, 3H), 3.24 (dd, *J* = 13.22, 6.87 Hz, 2H), 2.32 (t, *J* = 7.41, 7.41 Hz, 2H), 1.99-1.94 (m, 3H), 1.91 (s, 2H), 1.73-1.59 (m, 15H), 1.56-1.48 (m, 2H), 1.41-1.31 (m, 2H). ¹³C NMR (100 MHz, CDCl₃): δ ppm 173.95, 170.81, 51.78, 51.42, 42.56, 39.01, 36.70, 33.79, 32.62, 29.33, 28.56, 26.36, 24.39. LC-MS: system B, gradient 10% → 90% ACN/(0.1% TFA/H₂O): R_t (min): 8.71 (ESI-MS (m/z): 322.20 (M + H⁺)).

Ada-Ahx-OH (28). Methyl ester **27** (2.79 g, 8.68 mmol) was dissolved in THF (35 mL) and cooled to 0°C. An aqueous solution of LiOH (1M, 1.1 eq., 9.54 mmol, 9.54 mL) was added and the reaction was stirred at 0°C for 12 hours after which TLC analysis indicated complete consumption of starting material. Water (50 mL) was added and the mixture was extracted twice with EtOAc. Next, the aqueous layer was acidified with concentrated HCl to pH1 and extracted again with EtOAc (2x). The latter two combined organic layers were dried (MgSO₄) and concentrated under reduced pressure, which yielded the title compound (yield: 2.63 g, 8.57 mmol, 99%) as a colorless solid. ¹H NMR (400 MHz, CDCl₃): δ ppm 10.87 (s, 1H), 5.95 (t, *J* = 5.56, 5.56 Hz, 1H), 3.24 (dd, *J* = 13.16, 6.81 Hz, 2H), 2.34 (t, *J* = 7.34, 7.34 Hz, 2H), 1.99-1.92 (m, 5H), 1.73-1.58 (m, 14H), 1.53 (td, *J* = 14.65, 7.37, 7.37 Hz, 2H), 1.43-1.33 (m, 2H). ¹³C NMR (100 MHz, CDCl₃): δ ppm 177.96, 171.55, 51.49, 42.48, 39.15, 36.62, 33.86, 32.63, 29.11, 28.51, 26.24, 24.20. LC-MS: system B, gradient 10% → 90% ACN/(0.1% TFA/H₂O): R_t (min): 7.49 (ESI-MS (m/z): 308.13 (M + H⁺)).

Ada-Ahx₃-OMe (29). Methyl 6-(6-(tert-butoxycarbonylamino)hexanamido)hexanoate (3.37 g, 9.39 mmol) was dissolved in DCM/TFA (1/1, v/v) and stirred for 30 minutes before being coevaporated with toluene (3x). Ada-Ahx-OH **28** (2.63 g, 8.57 mmol) was dissolved in DMF. HCTU (4.08 g, 9.86 mmol, 1.15 eq) and DiPEA (5.12 mL, 31 mmol, 3.3 equiv.) were added and the mixture was stirred for 10 minutes. Methyl 6-(hexanamido)hexanoate TFA salt in DMF was added, and the mixture was stirred for 2h. The mixture was concentrated, dissolved in DCM, washed with 1M HCl (2x), sat. aq. NaHCO₃ (4x) and brine. After drying with MgSO₄ and concentration, the title compound was obtained as a colorless solid (yield: 4.10 g, 7.49 mmol, 87%) after column purification (MeOH/EtOAc (0-15%)). ¹H NMR (400 MHz, CDCl₃): δ ppm 6.42 (t, *J* = 5.67, 5.67 Hz, 1H), 6.38 (t, *J* = 5.61, 5.61 Hz, 1H), 6.13 (t, *J* = 5.60, 5.60 Hz, 1H), 3.66 (s, 3H), 3.25-3.18 (m, 6H), 2.31 (t, *J* = 7.43, 7.43 Hz, 2H), 2.18 (t, *J* = 7.42, 7.42 Hz, 4H), 1.98-1.94 (m, 3H), 1.92 (s, 2H), 1.73-1.58 (m, 18H), 1.56-1.47 (m, 6H), 1.39-1.29 (m, 6H). ¹³C NMR (100 MHz, CDCl₃): δ ppm 173.95, 172.97, 172.92, 171.02, 51.54, 51.37, 42.52, 39.07, 39.00, 36.65, 36.27, 33.75, 32.57, 29.28, 29.15, 28.51, 26.40, 26.38, 26.29, 25.18, 25.15, 24.39. LC-MS: system B, gradient 10% → 90% ACN/(0.1% TFA/H₂O): R_t (min): 7.93 (ESI-MS (m/z): 548.33 (M + H⁺)).

Ada-Ahx₃-OH (22). Methyl ester **29** (4.10 g, 7.49 mmol) was dissolved in THF/MeOH 5:1 (35 mL) and cooled to 0°C. An aqueous solution of LiOH (1M, 1.1 eq., 8.24 mmol, 8.24 mL) was added and the reaction was stirred at RT for 12 hours after which TLC analysis indicated complete consumption of starting material. Water (50 mL) was added and the mixture was extracted twice with EtOAc. Next, the aqueous layer was acidified with concentrated HCl to pH1 and extracted with DCM (3x). The combined DCM layers were dried (MgSO₄) and concentrated under reduced pressure, which yielded the title compound (yield: 3.79 g, 7.12 mmol, 95%) as a colorless solid. ¹H NMR (400 MHz, MeOD): δ ppm 7.96-7.90 (m, 2H), 7.86-7.79 (m, 1H), 3.19-3.11 (m, 6H), 2.29 (t, *J* = 7.35, 7.35 Hz, 2H), 2.17 (t, *J* = 7.45, 7.45 Hz, 4H), 1.97-1.93 (m, 3H), 1.91 (s, 2H), 1.74 (d, *J* = 12.27 Hz, 3H), 1.69-1.57 (m, 15H), 1.55-1.46 (m, 6H), 1.40-1.28 (m, 6H). ¹³C NMR (100 MHz, MeOD): 177.40, 175.97, 173.74, 51.91, 43.79, 40.21, 37.95, 37.02, 34.83, 33.81, 30.24, 30.19, 30.14, 27.68, 27.58, 27.53, 26.74, 25.75. LC-MS: system B, gradient 10% → 90% ACN/(0.1% TFA/H₂O): R_t (min): 7.21 (ESI-MS (m/z): 534.33 (M + H⁺)).


General protocol for azide couplings

The Boc-protected warhead was dissolved in TFA:DCM (1:1, v/v) and stirred for 20 minutes.

Coevaporation with toluene (3x) afforded the warhead TFA-salt, which was used without further purification. The appropriate hydrazide (**16** or **18**) was dissolved in 1:1 DMF:DCM (v/v) and cooled to -30°C. *t*BuONO (1.1 eq) and HCl (2.8 eq, 4M sln. in 1,4-dioxane) were added, and the mixture was stirred for 3h at -30°C after which TLC analysis (10% MeOH/DCM, v/v) showed complete consumption of the starting material. The warhead-TFA salt was added to the reaction mixture as a solution in DMF with 1.1 equivalent of DiPEA. A further 3.9 equivalents were added to the reaction mixture, and this mixture was allowed to warm to RT slowly overnight. The mixture was diluted with EA and extracted with H₂O (3x). The organic layer was dried over MgSO₄ and purified by flash column chromatography.

General protocol for block couplings

The Boc-protected tripeptide was dissolved in TFA:DCM (1:1, v/v) and stirred for 20 minutes. Coevaporation with toluene (3x) afforded the tripeptide TFA-salt, which was used without further purification. The carboxylic acid (1 equivalent **21** or **22**) was dissolved in DCM:DMF (1/1). HBTU (1.1 equiv), DiPEA (3.5 equiv.) were added and the mixture was stirred for 5 min. A solution of the tripeptide TFA salt in DMF was added and the mixture was stirred for 2h before being concentrated. The residue was taken up in DCM, washed with 1M HCl (2x), sat. aq. NaHCO₃ (4x), brine, and dried with Na₂SO₄. The residue was purified by flash column chromatography.




Cbz-Leu₂-leucinylnyl vinyl diethylphosphonate (IIa). Following the general procedure for azide coupling the title compound was obtained from Boc-leucinylnyl vinyl diethylphosphonate **23** (98 mg, 280 μmol, 1.1 equiv.) and Cbz-Leu₂-NHNH₂ **16** (100 mg, 254 μmol, 1 equiv). Purification by flash chromatography (MeOH:DCM (0-3%)) gave the title compound **IIa** (71 mg, 117 μmol, 46%). α_D^{20} -50.6° (c = 1.00, CHCl₃). IR (film) 3269, 2955, 2870, 1699, 1645, 1539, 1468, 1387, 1367, 1232, 1024, 962 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ ppm 7.85-7.70 (m, 1H), 7.36-7.22 (m, 5H), 6.78-6.62 (m, 2H), 5.85-5.72 (m, 1H), 5.14-4.97 (m, 2H), 4.70-4.54 (m, 2H), 4.45-4.35 (m, 1H), 4.08-3.93 (m, 4H), 1.83-1.68 (m, 1H), 1.66-1.31 (m, 8H), 1.32-1.20 (m, 6H), 0.94-0.77 (m, 18H). ¹³C NMR (100 MHz, CDCl₃) δ ppm 172.36, 171.29, 156.21, 153.02, 152.99, 136.31, 128.17, 127.69, 127.50, 116.21, 114.35, 66.43, 61.65, 61.58, 61.52, 53.24, 51.77, 49.28, 49.06, 42.64, 41.37, 40.74, 24.62, 24.53, 24.41, 24.36, 22.82, 22.73, 22.62, 22.43, 22.17, 22.09, 21.57, 16.11, 16.08, 16.05, 16.02. HRMS: calcd. for [C₃₉H₅₃N₃O₅P]⁺ 610.36156, found 610.36163.

Boc-Leu₂-leucinylnyl vinyl diethylphosphonate (30). Following the general procedure for azide coupling the title compound was obtained from Boc-leucinylnyl vinyl diethylphosphonate **23** (86 mg, 0.246 mmol, 1.1 equiv.) and Boc-Leu₂-NHNH₂ **18** (80 mg, 0.224 mmol, 1 equiv). Purification by flash chromatography EA:tol (50-100%) gave the title compound (118 mg, 0.205 mmol, 92%). ¹H NMR (400 MHz, CDCl₃): δ ppm 7.48-7.40 (m, 1H), 6.72 (ddd, *J*₁ = 22.2 Hz, *J*₂ = 17.2 Hz, *J*₃ = 5.2 Hz, 1H), 5.81 (t, *J* = 18.5 Hz, 2H), 5.56-5.50 (m, 1H), 4.72-4.63 (m, 1H), 4.55-4.48 (m, 1H), 4.12-4.00 (m, 5H), 1.75-1.20 (m, 25H), 0.95-0.86 (m, 18H). ¹³C NMR (100 MHz, CDCl₃): δ ppm 172.68, 171.22, 155.84, 152.60, 152.56, 116.90, 115.05, 80.00, 61.77, 61.72, 61.67, 53.26, 51.82, 49.48, 49.26, 43.14, 40.79, 40.61, 28.21, 24.64, 22.80, 22.70, 22.05, 21.95, 21.87, 16.26, 16.20.

Azido-Phe-Leu₂-leucinyl vinyl diethylphosphonate (IIb). Following the general procedure for block coupling, the title compound was obtained from Boc-Leu₂-leucinyl vinyl diethylphosphonate **30** (118 mg, 205 μ mol) and azido-phenylalanine **21** (44 mg, 230 μ mol, 1.1 equiv.). Flash column chromatography (EA:tol (50-100%)) yielded **IIb** (68 mg, 100 μ mol, 50%). α_D^{20} -36.8° (c = 1.00, CHCl₃). IR (film) 3277, 2957, 2926, 2112, 1641, 1541, 1468, 1387, 1367, 1226, 1163, 1053, 1024, 964 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ ppm 7.33-7.19 (m, 5H), 7.08-6.99 (m, 1H), 6.68 (ddd, *J* = 22.22, 17.15, 5.33 Hz, 1H), 5.77 (t, *J* = 17.2 Hz, 1H), 4.70-4.60 (m, 1H), 4.55-4.45 (m, 2H), 4.25 (dd, *J* = 8.25, 4.15 Hz, 1H), 4.12-3.96 (m, 4H), 3.22 (dd, *J* = 14.17, 3.67 Hz, 1H), 3.04 (dd, *J* = 14.12, 8.27 Hz, 1H), 1.77-1.16 (m, 15H), 1.00-0.78 (m, 18H). ¹³C NMR (100 MHz, CD₃OD): δ ppm 171.56, 171.05, 168.88, 152.42, 135.94, 129.37, 128.55, 127.14, 117.06, 115.20, 64.64, 61.89, 61.83, 61.76, 51.89, 51.62, 49.56, 49.34, 43.18, 41.03, 40.91, 38.00, 29.64, 24.81, 24.72, 24.48, 22.78, 22.74, 22.54, 22.50, 22.07, 21.99, 16.32, 16.29, 16.26, 16.23. HRMS: calcd. for [C₃₂H₅₄N₆O₆P]⁺ 649.3837, found 649.38385.

Ada-Ahx₃-Leu₂-leucinyl vinyl diethylphosphonate (IIc). Following the general procedure for block coupling, the title compound was obtained from Boc-Leu₂-leucinyl vinyl diethylphosphonate **30** (122 mg, 212 μ mol, 1 equiv.) and Ada-Ahx₃-OH **22** (124 mg, 233 μ mol, 1.1 equiv.). Flash column chromatography (MeOH:DCM (2-10%)) yielded **IIc** (149 mg, 150 μ mol, 71%). α_D^{20} -38.2° (c = 1.00, MeOH). IR (film) 3277, 3072, 2928, 2905, 2868, 1638, 1545, 1452, 1367, 1234, 1053, 1028, 968 cm⁻¹. ¹H NMR (400 MHz, CD₃OD): δ ppm 8.14-8.03 (m, 3H), 7.96 (t, *J* = 5.14, 5.14 Hz, 2H), 7.89-7.84 (m, 1H), 6.67 (ddd, *J* = 22.07, 17.21, 4.83 Hz, 1H), 5.86-5.74 (m, 1H), 4.64-4.54 (m, 1H), 4.45-4.30 (m, 2H), 4.05 (p, *J* = 7.26, 4H), 3.18-3.11 (m, 6H), 2.25 (t, *J* = 7.28, 2H), 2.17 (t, *J* = 7.40 Hz, 4H), 1.97-1.89 (m, 5H), 1.80-1.25 (m, 45H), 0.98-0.87 (m, 18H). ¹³C NMR (100 MHz, CD₃OD): δ ppm 176.23, 175.88, 174.85, 174.15, 173.66, 154.79, 154.74, 117.24, 115.37, 63.43, 63.37, 53.50, 53.29, 51.91, 51.05, 50.83, 43.73, 43.49, 41.82, 41.72, 40.29, 40.24, 37.90, 37.02, 36.66, 33.75, 30.21, 30.14, 30.10, 27.64, 27.58, 27.55, 26.71, 26.57, 25.93, 25.88, 25.85, 23.46, 23.38, 22.19, 22.12, 22.03, 16.72, 16.66. HRMS calcd for [C₅₃H₉₆N₆O₉P]⁺ 991.69709, found 991.698.




Boc-Leu₂-leucinyl vinyl diphenylphosphinoyl (31). Following the general procedure for azide coupling the title compound was obtained from Boc-leucinyl-vinyl diphenylphosphinoyl **24** (380 mg, 0.92 mmol, 1.1 equiv.) and Boc-Leu₂-NHNH₂ **18** (300 mg, 0.84 mmol, 1 equiv.). Purification by flash chromatography EA:tol (30-70%, 3x) gave the title compound (221 mg, 0.345 mmol, 41%). ¹H NMR (400 MHz, CDCl₃): δ ppm 7.87-7.33 (m, 10H), 6.81 (d, *J* = 7.14 Hz, 1H), 6.73-6.42 (m, 2H), 5.47 (d, *J* = 5.53 Hz, 1H), 4.83-4.69 (m, 1H), 4.56-4.48 (m, 1H), 4.08-3.98 (m, 1H), 1.83-1.15 (m, 15H), 1.03-0.77 (m, 18H). ¹³C NMR (100 MHz, CDCl₃): δ ppm 172.49, 171.33, 155.89, 151.63, 133.49, 133.01, 132.44, 131.96, 131.60, 131.24, 131.15, 128.49, 128.42, 128.30, 121.26, 120.26, 79.95, 53.46, 51.96, 49.73, 49.56, 43.09, 40.90, 40.75, 28.18, 24.74, 24.67, 24.59, 22.80, 22.70, 22.08, 21.80.

Cbz-Leu₂-leucinyl vinyl diphenylphosphinoyl (IIIa). Following the general procedure for azide coupling the title compound was obtained from Boc-leucinyl-vinyl diphenylphosphinoyl **24** (179 mg, 280 μ mol, 1.1 equiv.) and Cbz-Leu₂-NHNH₂ **16** (100 mg, 254 μ mol, 1 equiv.). Purification by flash chromatography (MeOH:DCM (0-3%)) gave the title compound **IIIa** (79 mg, 117 μ mol, 46%).

α_D^{20} -56.8° (c = 1.00, CHCl₃). IR (film) 3271, 3059, 2955, 1701, 1645, 1539, 1437, 1387, 1367, 1263, 1236, 1171, 1121, 1105, 1043, 1028, 972 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ ppm 7.75 (d, *J* = 8.59 Hz, 1H), 7.71-7.60 (m, 4H), 7.54-7.24 (m, 11H), 6.90 (d, *J* = 7.88 Hz, 1H), 6.67-6.40 (m, 2H), 6.05 (d, *J* = 7.42 Hz, 1H), 5.12-4.95 (m, 2H), 4.78-4.68 (m, 1H), 4.59-4.51 (m, 1H), 4.22-4.13 (m, 1H), 1.80-1.19 (m, 9H), 0.92-0.72 (m, 18H). HRMS: calcd. for [C₃₉H₅₃N₃O₅P]⁺ 674.37173, found 674.37195.

Azido-Phe-Leu₂-leucinylnyl vinyl diphenylphosphin oxide (IIIb). Following the general procedure for block coupling, the title compound was obtained from Boc-Leu₂-leucinylnyl vinyl diphenylphosphin oxide **31** (75 mg, 117 μ mol) and azido-phenylalanine **21** (22 mg, 120 μ mol, 1.1 equiv.). Flash column chromatography (EA:tol (50-100%), 2x) yielded **IIIb** (71 mg, 100 μ mol, 85%). α_D^{20} -43.6° (c = 1.00, CHCl₃). IR 3281, 3059, 2955, 2928, 2870, 2112, 1641, 1541, 1437, 1387, 1367, 1173, 1121, 1105, 1028, 997 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ ppm 7.86-7.34 (m, 10H), 7.28-7.13 (m, 5H), 7.05 (d, *J* = 8.00 Hz, 1H), 6.60-6.37 (m, 2H), 4.82-4.70 (m, 1H), 4.63-4.54 (m, 1H), 4.49-4.41 (m, 1H), 4.28-4.22 (m, 1H), 3.19-3.10 (m, 1H), 3.04-2.95 (m, 1H), 1.81-1.16 (m, 9H), 0.94-0.71 (m, 18H). ¹³C NMR (100 MHz, CDCl₃): δ ppm 171.39, 171.09, 169.23, 151.88, 136.08, 133.01, 132.38, 131.92, 131.37, 131.27, 131.18, 131.08, 129.29, 128.66, 128.61, 128.54, 128.49, 127.00, 121.51, 120.50, 64.30, 51.95, 51.74, 49.79, 49.62, 43.16, 41.17, 40.59, 37.94, 24.85, 24.80, 24.46, 22.76, 22.70, 22.22, 22.00, 21.91. HRMS: calcd. for [C₄₀H₅₄N₆O₄P]⁺ 713.39387, found 713.39426.

Ada-Ahx₃-Leu₂-leucinylnyl vinyl diphenylphosphin oxide (IIIc). Following the general procedure for block coupling, the title compound was obtained from Boc-Leu₂-leucinylnyl vinyl diphenylphosphin oxide **31** (72 mg, 113 μ mol) and Ada-Ahx₃-OH **22** (60 mg, 124 μ mol, 1.1 equiv.). Flash column chromatography (MeOH:DCM (5-11%)) yielded **IIIc** (101 mg, 96 μ mol, 85%). α_D^{20} -41.0° (c = 1.00, MeOH). IR 3277, 2928, 2904, 2849, 1638, 1545, 1437, 1367, 1277, 1171, 1121, 1105 cm⁻¹. ¹H NMR (400 MHz, CD₃OD): δ ppm 8.14 (d, *J* = 8.26 Hz, 1H), 8.08 (d, *J* = 6.47 Hz, 1H), 8.04 (d, *J* = 7.37 Hz, 1H), 7.99-7.91 (m, 2H), 7.89-7.82 (m, 1H), 7.74-7.47 (m, 10H), 6.73-6.46 (m, 2H), 4.73-4.63 (m, 1H), 4.43-4.35 (m, 1H), 4.34-4.26 (m, 1H), 3.20-3.08 (m, 6H), 2.25 (t, *J* = 7.31, 7.31 Hz, 1H), 2.16 (t, *J* = 7.24, 7.24 Hz, 1H), 1.96-1.89 (m, 5H), 1.79-1.25 (m, 39H), 0.98-0.82 (m, 18H). ¹³C NMR (100 MHz, CD₃OD): δ ppm 176.41, 175.94, 174.98, 174.31, 173.73, 153.55, 133.90, 133.49, 132.84, 132.72, 132.35, 132.28, 132.25, 132.18, 130.02, 130.00, 129.90, 129.88, 121.76, 120.75, 53.75, 53.46, 51.93, 51.51, 51.34, 43.74, 43.43, 41.75, 41.62, 40.30, 40.25, 37.90, 37.03, 36.65, 33.76, 30.22, 30.12, 27.64, 27.60, 27.55, 26.71, 26.54, 25.98, 25.94, 25.89, 23.45, 23.40, 23.30, 22.14, 22.08, 21.98. HRMS: calcd. for [C₆₁H₉₆N₆O₇P]⁺ 1055.70726, found 1055.70846.




Boc-Leu₂-leucinylnyl vinyl 1-adamantylmethylsulfone (32). Following the general procedure for azide coupling the title compound was obtained from Boc-leucinylnyl vinyl 1-adamantylsulfone **26** (410 mg, 1 mmol, 1.1 equiv.) and Boc-Leu₂-NHNH₂ **18** (330 mg, 0.91 mmol, 1 equiv.). Purification by flash chromatography EA:tol (0-40%) gave the title compound (383 mg, 0.6 mmol, 66%). ¹H NMR (400 MHz, CDCl₃): δ ppm 7.36-7.22 (m, 1H), 6.77 (dd, *J* = 15.18, 4.95 Hz, 1H), 6.73-6.71 (m, 1H), 6.42 (d, *J* = 15.11 Hz, 1H), 5.40 (d, *J* = 4.68 Hz, 1H), 4.81-4.71 (m, 1H), 4.47 (dd, *J* = 14.48, 7.85 Hz, 1H), 4.09-4.00 (m, 1H), 2.14 (s, 3H), 2.01-1.91 (m, 6H), 1.78-1.46 (m, 15H), 1.44 (s, 9H), 0.96-0.87 (m, 18H). ¹³C NMR (100 MHz, CDCl₃): δ ppm 172.61, 171.23, 156.05, 150.22, 123.19, 80.19, 59.62, 53.61, 51.97, 48.14, 42.85, 40.75, 40.42, 35.71, 34.44, 28.23, 28.03, 24.87, 24.65, 22.80, 22.62, 22.19, 21.96, 21.82.

Cbz-Leu₂-leucinyl vinyl 1-adamantylsulfone (IVa). Following the general procedure for azide coupling the title compound was obtained from Boc-leucinyl vinyl 1-adamantylsulfone **26** (206 mg, 0.5 mmol, 1.1 equiv.) and Cbz-Leu₂-NHNH₂ **16** (177 mg, 0.45 mmol, 1 equiv). Purification by flash chromatography (EA:tol (0-25%)) gave the title compound (271 mg, 400 μ mol, 89%). α_D^{20} -44.4° (c = 1.00, CHCl₃). IR (film) 3287, 2957, 2914, 1699, 1645, 1539, 1454, 1263, 1134, 1047, 1028, 976 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ ppm 7.44-7.28 (m, 5H), 6.88 (d, *J* = 6.69 Hz, 1H), 6.76 (dd, *J* = 15.13, 5.06 Hz, 1H), 6.37 (d, *J* = 15.09 Hz, 1H), 5.94 (d, *J* = 6.57 Hz, 1H), 5.14-5.01 (m, 2H), 4.79-4.69 (m, 1H), 4.51 (q, *J* = 7.57 Hz, 1H), 4.19 (dd, *J* = 13.60, 6.89 Hz, 1H), 2.11 (s, 3H), 1.99-1.87 (m, 6H), 1.84-1.33 (m, 15H), 0.93-0.82 (m, 18H). ¹³C NMR (100 MHz, CDCl₃): δ ppm 172.41, 171.28, 156.69, 150.59, 136.25, 128.68, 128.35, 128.01, 123.19, 67.17, 59.86, 54.01, 52.08, 48.37, 42.94, 40.95, 35.89, 34.66, 28.20, 25.15, 24.89, 24.78, 22.97, 22.90, 22.68, 22.44, 22.19, 22.04. HRMS Calcd. for [C₃₇H₅₈N₃O₆S]⁺ 672.40408, found 672.40442.

Azido-Phe-Leu₂-leucinyl vinyl 1-adamantylsulfone (IVb). the general procedure for block coupling, the title compound was obtained from Boc-Leu₂-leucinyl vinyl 1-adamantylsulfone **32** (140 mg, 220 μ mol, 1 equiv) and azido-phenylalanine **21** (46 mg, 242 μ mol, 1.1 equiv.). Flash column chromatography (EA:tol (20-40%)) yielded **IVb** (81 mg, 112 μ mol, 52%). α_D^{20} -35.0° (c = 1.00, CHCl₃). IR (film) 3287, 2955, 2912, 2112, 1643, 1541, 1456, 1304, 1283, 1259, 1136 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ ppm 7.49 (d, *J* = 8.19 Hz, 1H), 7.38-7.11 (m, 5H), 6.77 (dd, *J* = 15.11, 5.34 Hz, 1H), 6.38 (d, *J* = 15.13 Hz, 1H), 4.82-4.69 (m, 1H), 4.62-4.52 (m, 2H), 4.22 (dd, *J* = 8.26, 4.03 Hz, 1H), 3.19 (dd, *J* = 14.15, 3.83 Hz, 1H), 3.04 (dd, *J* = 14.13, 8.53 Hz, 1H), 2.13 (s, 3H), 1.99-1.88 (m, 6H), 1.84-1.32 (m, 15H), 0.94-0.81 (m, 18H). ¹³C NMR (100 MHz, CDCl₃): δ ppm 171.65, 171.13, 169.03, 150.21, 135.95, 129.29, 128.58, 127.16, 123.33, 64.57, 59.72, 51.92, 51.68, 48.26, 42.87, 41.09, 41.06, 37.89, 35.71, 34.55, 28.04, 24.99, 24.73, 24.53, 22.72, 22.69, 22.24, 22.16, 22.04. HRMS calcd. for [C₃₈H₅₉N₆O₅S]⁺ 711.42622, found 711.42633.

Ada-Ahx₃-Leu₂-leucinyl vinyl-1-adamantylsulfone (IVc). Following the general procedure for block coupling, the title compound was obtained from Boc-Leu₂-leucinyl vinyl 1-adamantylsulfone **32** (140 mg, 220 μ mol, 1 equiv.) and Ada-Ahx₃-OH **22** (252 mg, 242 μ mol, 1.1 equiv.). Flash column chromatography (EA:MeOH (0-7%)) yielded **IVc** (158 mg, 152 μ mol, 69%). α_D^{20} -34.0° (c = 1.00, MeOH). IR (film) 3285, 2910, 2851, 1639, 1541, 1454, 1279, 1134 cm⁻¹. ¹H NMR (400 MHz, CD₃OD): δ ppm 8.08-7.98 (m, 1H), 7.96-7.87 (m, 2H), 7.84-7.78 (m, 1H), 6.69 (dd, *J* = 15.14, 4.90 Hz, 1H), 6.41 (d, *J* = 15.11 Hz, 1H), 4.67-4.60 (m, 1H), 4.34 (t, *J* = 7.29 Hz, 1H), 4.24 (dd, *J* = 8.46, 6.37 Hz, 1H), 3.19-3.04 (m, 6H), 2.27-2.18 (m, 2H), 2.18-2.04 (m, 7H), 2.00-1.82 (m, 12H), 1.84-1.38 (m, 29H), 1.37-1.22 (m, 6H), 0.97-0.82 (m, 18H). ¹³C NMR (100 MHz, CD₃OD): δ ppm 176.40, 175.89, 175.81, 175.00, 174.18, 173.68, 152.03, 124.26, 60.82, 53.92, 53.32, 51.93, 51.88, 49.64, 43.74, 43.15, 41.56, 40.31, 40.26, 40.18, 40.13, 37.91, 37.04, 36.99, 36.83, 36.58, 35.64, 33.76, 30.22, 30.13, 29.59, 27.65, 27.62, 27.56, 26.72, 26.53, 26.03, 25.92, 25.89, 23.44, 23.40, 22.11, 22.01, 21.95. HRMS calcd. for [C₅₉H₁₀₁N₆O₈S]⁺ 1053.73961, found 1073.74023.




Boc-Leu₂-leucinyl vinyl 1-adamantylmethylsulfone (33). Following the general procedure for azide coupling the title compound was obtained from Boc-leucinyl vinyl 1-adamantylmethylsulfone **3** (800 mg, 1.88 mmol, 1.1 equiv.) and Boc-Leu₂-NHNH₂ **18** (610 mg, 1.71 mmol, 1 equiv). Purification by

flash chromatography EA:tol (0-20%) gave the title compound **33** (1.01 g, 1.55 mmol, 91%). ¹H NMR (400 MHz, CDCl₃): δ ppm 7.38 (d, *J* = 8.32 Hz, 1H), 7.08 (d, *J* = 5.80 Hz, 1H), 6.78 (dd, *J* = 15.06, 5.24 Hz, 1H), 6.52 (d, *J* = 15.03 Hz, 1H), 5.55 (d, *J* = 5.54 Hz, 1H), 4.78-4.69 (m, 1H), 4.52-4.44 (m, 1H), 4.21-4.07 (m, 1H), 2.80 (s, 2H), 2.02-1.97 (m, 3H), 1.84-1.81 (m, 6H), 1.76-1.48 (m, 18H), 1.44 (s, 9H), 0.96-0.86 (m, 18H). ¹³C NMR (100 MHz, CDCl₃): δ ppm 172.76, 171.37, 155.83, 146.35, 130.80, 79.89, 66.90, 53.26, 51.95, 47.60, 42.72, 41.93, 40.48, 36.27, 34.16, 28.19, 24.69, 24.56, 22.76, 22.70, 22.55, 22.12, 21.91.

Cbz-Leu₂-leucinylnyl vinyl 1-adamantylmethysulfone (Va). Following the general procedure for azide coupling the title compound was obtained from Boc-leucinylnyl vinyl 1-adamantylmethysulfone **3** (309 mg, 0.73 mmol, 1.1 equiv.) and Cbz-Leu₂-NHNH₂ **16** (260 mg, 0.66 mmol, 1 equiv). Purification by flash chromatography (EA:tol (0-25%)) gave the title compound **Va** (365 mg, 530 μmol, 73%). α_D²⁰ -50.6° (c = 1.00, CHCl₃). IR (film) 3290, 2959, 2907, 1699, 1645, 1539, 1456, 1263, 1240, 1132, 1139, 1028 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ ppm 7.75-7.49 (m, 2H), 7.36-7.25 (m, 5H), 6.76 (dd, *J* = 15.04, 5.19 Hz, 1H), 6.47 (d, *J* = 14.97 Hz, 1H), 6.43-6.29 (m, 1H), 5.14-4.97 (m, 2H), 4.76-4.65 (m, 1H), 4.61-4.52 (m, 1H), 4.41-4.31 (m, 1H), 2.75 (s, 2H), 2.00-1.95 (m, 3H), 1.85-1.22 (m, 21H), 0.94-0.78 (m, 18H). ¹³C NMR (100 MHz, CDCl₃): δ ppm 172.44, 171.37, 156.33, 146.66, 136.24, 130.61, 128.36, 127.94, 127.60, 66.92, 66.71, 53.47, 51.89, 47.62, 42.62, 41.96, 41.32, 40.64, 36.29, 34.20, 28.22, 24.82, 24.53, 22.78, 22.62, 22.56, 22.34, 21.76. HRMS calcd. for [C₃₈H₆₀N₃O₆S]⁺ 686.41973, found 686.42012.

Azido-Phe-Leu₂-leucinylnyl vinyl 1-adamantylmethysulfone (Vb). Following the general procedure for block coupling, the title compound was obtained from Boc-Leu₂-leucinylnyl vinyl 1-adamantylmethysulfone **33** (232 mg, 357 μmol, 1.1 equiv) and azido-phenylalanine **21** (62 mg, 320 μmol, 1 equiv.). Flash column chromatography (EA:tol (0-10-50%)) yielded **Vb** (144 mg, 200 μmol, 62%). α_D²⁰ -35.0° (c = 1.00, CHCl₃). IR (film) 3277, 2957, 2907, 2851, 2110, 1638, 1541, 1454, 1387, 1313, 1265, 1132, 1119, 968 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ ppm 7.69 (d, *J* = 6.39 Hz, 1H), 7.54 (d, *J* = 8.23 Hz, 1H), 7.48 (d, *J* = 8.11 Hz, 1H), 7.33-7.13 (m, 5H), 6.75 (dd, *J* = 15.07, 5.68 Hz, 1H), 6.44 (d, *J* = 15.02 Hz, 1H), 4.73-4.63 (m, 2H), 4.62-4.54 (m, 1H), 4.24 (dd, *J* = 8.64, 4.16 Hz, 1H), 3.15 (dd, *J* = 14.24, 3.68 Hz, 1H), 3.04 (dd, *J* = 14.23, 8.72 Hz, 1H), 2.77 (s, 2H), 2.02-1.95 (m, 3H), 1.85-1.32 (m, 21H), 0.97-0.80 (m, 18H). ¹³C NMR (100 MHz, CDCl₃): δ ppm 171.72, 171.42, 168.96, 146.10, 135.97, 131.02, 129.23, 128.57, 127.14, 66.88, 64.41, 51.95, 51.54, 47.83, 42.75, 42.02, 41.42, 40.87, 37.84, 36.32, 34.29, 28.26, 24.90, 24.64, 24.55, 22.67, 22.65, 22.46, 22.37, 21.98. HRMS calcd. for [C₃₉H₆₁N₆O₅S]⁺ 725.44187, found 725.44237.

Ada-Ahx₃-Leu₂-leucinylnyl vinyl-1-adamantylmethysulfone (Vc). Following the general procedure for block coupling, the title compound was obtained from Boc-Leu₂-leucinylnyl vinyl 1-adamantylmethysulfone **33** (227 mg, 348 μmol, 1.1 equiv.) and Ada-Ahx₃-OH **22** (170 mg, 320 μmol, 1.1 equiv.). Flash column chromatography (MeOH:DCM (0-7%)) yielded **Vc** (313 mg, 290 μmol, 92%). α_D²⁰ -33.2° (c = 1.00, MeOH). IR (film) 3277, 3080, 2903, 2849, 1636, 1541, 1452, 1367, 1343, 1281, 1117, 1034 cm⁻¹. ¹H NMR (400 MHz, CD₃OD): δ ppm 8.06 (t, *J* = 7.28, 7.28 Hz, 2H), 7.91 (t, *J* = 4.96, 4.96 Hz, 2H), 7.81 (t, *J* = 4.94, 4.94 Hz, 1H), 6.72 (dd, *J* = 15.10, 5.01 Hz, 1H), 6.56 (d, *J* = 15.11 Hz, 1H), 4.70-4.61 (m, 1H), 4.43-4.29 (m, 2H), 3.21-3.09 (m, 6H), 2.90 (s, 2H), 2.32-2.21 (m, 2H), 2.17 (t, *J* = 7.33, 7.33 Hz, 4H), 2.01-1.23 (m, 61H), 0.99-0.85 (m, 18H). ¹³C NMR (100 MHz, CD₃OD): δ ppm 176.18, 176.10, 175.74, 175.65, 174.88, 174.80, 174.09, 174.01, 173.52, 147.66, 132.22, 67.65, 53.60, 53.21, 51.87, 49.15, 49.06, 43.66, 43.16, 43.01, 41.56, 41.47, 40.24, 40.19, 37.86, 37.52, 36.99, 36.57, 35.12, 33.69, 30.15, 30.10, 30.03, 29.75, 27.58, 27.54, 27.49, 26.65, 26.50, 25.87, 25.82, 25.76, 23.49, 22.18, 22.06, 22.02. HRMS calcd. for [C₆₀H₁₀₃N₆O₈S]⁺ 1067.75526, found 1067.75646.




Boc-Leu₂-(R)-5-amino-5,6-dihydro-pyran-2-one (35). Following the general procedure for azide coupling the title compound was obtained from (R)-5-(Boc-amino)-5,6-dihydro-pyran-2-one **34**¹ (103 mg, 484 μ mol, 1.1 equiv.) and Boc-Leu₂-NHNH₂ **18** (158 mg, 440 μ mol, 1 equiv). Purification by flash chromatography (EA:tol (30-60%)) gave the title compound (129 mg, 290 μ mol, 67%). ¹H NMR (400 MHz, CDCl₃): δ ppm 7.68-7.51 (m, 1H), 6.92-6.84 (m, 2H), 6.08 (d, J = 9.67 Hz, 1H), 5.32-5.22 (m, 1H), 4.83-4.71 (m, 1H), 4.51-4.43 (m, 2H), 4.33-4.24 (m, 1H), 4.13-4.03 (m, 1H), 1.78-1.48 (m, 6H), 1.43 (s, 9H), 0.99-0.86 (m, 12H). ¹³C NMR (100 MHz, CDCl₃): δ ppm 172.87, 172.39, 162.76, 155.99, 144.85, 122.45, 80.39, 69.69, 53.58, 51.85, 41.77, 40.61, 28.19, 24.72, 22.85, 21.74.

Cbz-Leu₂-(R)-5-amino-5,6-dihydro-pyran-2-one (VIa). Following the general procedure for azide coupling the title compound was obtained from (R)-5-(Boc-amino)-5,6-dihydro-pyran-2-one **34**¹ (36 mg, 160 μ mol, 1.1 equiv.) and Cbz-Leu₂-NHNH₂ **16** (59 mg, 150 μ mol, 1 equiv). Purification by flash chromatography (EA:tol (20-50%)) gave the title compound **VIa**. α_D^{20} -106.8° (c = 0.94, CHCl₃). IR (film) 3288, 2957, 2930, 1717, 1699, 1645, 1533, 1456, 1387, 1261, 1231, 1092, 1040 cm⁻¹. ¹H NMR (400 MHz, CD₃OD): δ ppm 7.40-7.26 (m, 5H), 6.93 (dd, J = 9.74, 4.51 Hz, 1H), 6.10 (dd, J = 9.79, 1.05 Hz, 1H), 5.09 (s, 2H), 4.72-4.65 (m, 1H), 4.48 (dd, J = 11.56, 4.44 Hz, 1H), 4.38 (dd, J = 9.74, 4.96 Hz, 1H), 4.27 (dd, J = 11.52, 5.03 Hz, 1H), 4.11 (t, J = 7.47 Hz, 1H), 1.77-1.26 (m, 6H), 0.99-0.85 (m, 12H). ¹³C NMR (100 MHz, CDCl₃): δ ppm 172.47, 172.20, 162.88, 156.69, 144.16, 135.91, 130.85, 128.55, 128.28, 127.91, 122.85, 69.91, 68.14, 67.31, 54.28, 51.83, 41.57, 40.88, 40.45, 24.88, 24.76, 22.87, 21.73, 21.68. HRMS calcd. for [C₂₅H₃₆N₃O₆]⁺ 474.25986, found 496.24181.

Azido-Phe-Leu₂-(R)-5-amino-5,6-dihydro-pyran-2-one (VIb). Following the general procedure for block coupling, the title compound was obtained from Boc-Leu₂-(R)-5-amino-5,6-dihydro-pyran-2-one **35** (44 mg, 100 μ mol, 1 equiv) and azido-phenylalanine **21** (21 mg, 110 μ mol, 1.1 equiv.). Flash column chromatography (EA:PE (20-70%)) yielded **VIb** (19 mg, 37 μ mol, 37%). IR (film) 3279, 2957, 2926, 2112, 1734, 1645, 1541, 1456, 1229, 1094 cm⁻¹. ¹H NMR (400 MHz, CD₃OD): δ ppm 7.34-7.19 (m, 5H), 6.94 (dd, J = 9.76, 4.56 Hz, 1H), 6.11 (d, J = 4.56 Hz, 1H), 4.72-4.64 (m, 1H), 4.50 (dd, J = 11.53, 4.36 Hz, 1H), 4.41-4.34 (m, 2H), 4.30 (dd, J = 11.55, 4.79 Hz, 1H), 3.19 (dd, J = 14.00, 4.92 Hz, 1H), 2.98 (dd, J = 13.98, 8.48 Hz, 1H), 1.79-1.48 (m, 6H), 1.02-0.83 (m, 12H). ¹³C NMR (100 MHz, CD₃OD): δ ppm 174.91, 174.33, 171.74, 146.37, 137.87, 130.47, 129.59, 128.04, 123.34, 71.12, 65.51, 53.36, 53.13, 43.16, 41.79, 41.76, 38.67, 25.92, 25.83, 23.45, 23.40, 22.03, 21.97. HRMS calcd for [C₂₆H₃₇N₆O₅]⁺ 513.28199, found 513.28168.

Ada-Ahx₃-Leu₂-(R)-5-amino-5,6-dihydro-pyran-2-one (VIc). Following the general procedure for block coupling, the title compound was obtained from Boc-Leu₂-(R)-5-amino-5,6-dihydro-pyran-2-one **35** (44 mg, 100 μ mol, 1 equiv.) and Ada-Ahx₃-OH **22** (57 mg, 110 μ mol, 1.1 equiv.). Flash column chromatography (EA:MeOH (0-15%)) yielded **VIc** (76 mg, 89 μ mol, 89%). α_D^{20} -54.0° (c = 1.00, MeOH). IR (film) 3285, 2905, 2851, 1732, 1641, 1545, 1439, 1202, 1175, 1134, 1094 cm⁻¹. ¹H NMR (400 MHz, CD₃OD): δ ppm 8.49 (d, J = 7.28 Hz, 1H), 8.11 (d, J = 6.68 Hz, 1H), 8.07 (d, J = 7.32 Hz, 1H), 8.00-7.92 (m, 2H), 7.90-7.83 (m, 1H), 6.97-6.90 (m, 1H), 6.09 (d, J = 9.73 Hz, 1H), 4.74-4.63 (m, 1H), 4.54-4.45 (m, 1H), 4.43-4.24 (m, 3H), 3.22-3.06 (m, 6H), 2.25 (t, J = 7.09, 7.09 Hz, 2H), 2.18 (t, J = 7.02, 7.02 Hz, 4H), 1.01-0.86 (m, 12H), 1.99-1.89 (m, 5H), 1.81-1.20 (m, 36H). ¹³C NMR (100 MHz, CD₃OD): δ ppm 176.46, 176.02, 175.93, 175.08, 174.84, 174.75, 173.80, 146.64,

123.18, 71.00, 55.82, 53.55, 53.15, 51.96, 43.77, 43.33, 43.24, 41.84, 41.63, 40.32, 40.27, 40.19, 40.14, 37.93, 37.06, 37.01, 36.68, 33.79, 30.23, 30.17, 30.12, 27.66, 27.57, 26.72, 26.59, 25.93, 25.90, 23.51, 23.43, 22.02, 21.93. HRMS calcd. for $[C_{47}H_{79}N_6O_8]^+$ 855.59539, found 855.59589.




Boc-Leu₂-(5R, 6R)-5-amino-6-methyl-5,6-dihydropyran-2-one (37). Following the general procedure for azide coupling the title compound was obtained from (5R, 6R)-5-(Boc-amino)-6-methyl-5,6-dihydropyran-2-one **36ⁱⁱ** (112 mg, 495 μmol , 1.1 equiv.) and Boc-Leu₂-NHNH₂ **18** (161 mg, 450 μmol , 1 equiv). Purification by flash chromatography (EA:tol (30-60%)) gave the title compound **37** (168 mg, 370 μmol , 82%). ¹H NMR (400 MHz, CDCl₃): δ ppm 7.52 (d, J = 5.55 Hz, 1H), 7.12-7.00 (m, 1H), 6.85 (dd, J = 9.59, 5.77 Hz, 1H), 6.12 (d, J = 9.63 Hz, 1H), 5.28 (d, J = 6.31 Hz, 1H), 4.72-4.64 (m, 2H), 4.50-4.42 (m, 1H), 4.13-4.02 (m, 1H), 1.71-1.44 (m, 6H), 1.43 (s, 9H), 1.31 (d, J = 6.27 Hz, 3H), 0.97-0.87 (m, 12H). ¹³C NMR (100 MHz, CDCl₃): δ ppm 172.87, 172.71, 164.00, 155.84, 143.31, 122.73, 80.24, 75.98, 53.05, 51.94, 43.65, 40.83, 40.68, 28.14, 24.65, 22.86, 22.71, 21.88, 21.68, 15.98.

Cbz-Leu₂-(5R, 6R)-5-amino-6-methyl-5,6-dihydropyran-2-one (VIIa). Following the general procedure for azide coupling the title compound was obtained from (5R, 6R)-5-(Boc-amino)-6-methyl-5,6-dihydropyran-2-one **36ⁱⁱ** (36 mg, 160 μmol , 1.1 equiv.) and Cbz-Leu₂-NHNH₂ **16** (59 mg, 150 μmol , 1 equiv). Purification by flash chromatography (EA:tol (25-60%)) gave the title compound **VIIa** (13 mg, 27 μmol , 18%). α_D^{20} -278.8° (c = 0.16, CHCl₃). IR (film) 2957, 1734, 1717, 1699, 1684, 1668, 1639, 1558, 1541, 1506, 1456, 1387, 1250, 1067 cm^{-1} . ¹H NMR (400 MHz, CDCl₃): δ ppm 7.42-7.29 (m, 5H), 7.04 (d, J = 8.49 Hz, 1H), 6.83 (dd, J = 9.46, 6.03 Hz, 1H), 6.38 (d, J = 6.79 Hz, 1H), 6.15 (d, J = 9.54 Hz, 1H), 5.22 (d, J = 3.99 Hz, 1H), 5.19-5.03 (m, 2H), 4.71-4.60 (m, 2H), 4.48-4.38 (m, 1H), 4.11-4.03 (m, 1H), 1.83-1.39 (m, 6H), 1.28 (d, J = 6.26 Hz, 3H), 0.99-0.84 (m, 12H). ¹³C NMR (100 MHz, CDCl₃): δ ppm 172.37, 143.02, 128.57, 128.34, 128.19, 123.17, 78.36, 75.97, 70.12, 67.59, 54.38, 52.23, 43.75, 40.73, 40.67, 31.42, 24.99, 24.83, 23.00, 22.88, 21.74, 21.51, 16.23. HRMS calcd. for $[C_{26}H_{38}N_3O_6]^+$ 488.27551, found 488.27512.

Azido-Phe-Leu₂-(5R, 6R)-5-amino-6-methyl-5,6-dihydropyran-2-one (VIIb). Following the general procedure for block coupling, the title compound was obtained from Boc-Leu₂-(5R, 6R)-5-amino-6-methyl-5,6-dihydropyran-2-one **37** (32 mg, 70 μmol , 1 equiv) and azido-phenylalanine **21** (15 mg, 77 μmol , 1.1 equiv.). Flash column chromatography (EA:PE (20-65%)) yielded **VIIb** (22 mg, 42 μmol , 60%). 3281, 2955, 2926, 2870, 2112, 1736, 1639, 1533, 1456, 1387, 1251, 1069 cm^{-1} . ¹H NMR (400 MHz, CD₃OD): δ ppm 7.35-7.20 (m, 5H), 6.92 (dd, J = 9.60, 6.12 Hz, 1H), 6.15 (d, J = 9.63 Hz, 1H), 4.78-4.68 (m, 1H), 4.63 (dd, J = 5.92, 3.31 Hz, 1H), 4.44-4.35 (m, 2H), 4.16 (dd, J = 8.38, 4.96 Hz, 1H), 3.19 (dd, J = 14.02, 4.93 Hz, 1H), 2.98 (dd, J = 13.98, 8.46 Hz, 1H), 1.74-1.22 (m, 9H), 1.00-0.83 (m, 12H). ¹³C NMR (100 MHz, CD₃OD): δ ppm 174.19, 144.85, 133.33, 130.49, 129.58, 128.03, 123.70, 77.58, 65.55, 53.25, 45.21, 41.91, 41.78, 38.70, 25.94, 25.82, 23.42, 23.35, 22.13, 22.04, 16.73. HRMS calcd. for $[C_{27}H_{39}N_6O_5]^+$ 527.29764, found 527.29736.

Ada-Ahx₃-Leu₂-(5R, 6R)-5-amino-6-methyl-5,6-dihydropyran-2-one (VIIc). Following the general procedure for block coupling, the title compound was obtained from Boc-Leu₂-(5R, 6R)-5-amino-6-methyl-5,6-dihydropyran-2-one **37** (41 mg, 90 μmol , 1 equiv.) and Ada-Ahx₃-OH **22** (51 mg, 100 μmol , 1.1 equiv.). Flash column chromatography (EA:MeOH (0-15%)) yielded **VIIc** (31 mg, 35

μmol , 40%). α_D^{20} -100° ($c = 0.4$, MeOH). IR (film) 3285, 2905, 2851, 1734, 1639, 1541, 1456, 1369, 1257, 1204, 1069 cm^{-1} . ^1H NMR (400 MHz, CD_3OD): δ ppm 8.42 (d, $J = 8.28$ Hz, 1H), 8.10 (d, $J = 6.55$ Hz, 1H), 8.06 (d, $J = 6.41$ Hz, 1H), 7.99-7.91 (m, 2H), 7.89-7.83 (m, 1H), 6.95-6.87 (m, 1H), 6.14 (d, $J = 9.39$ Hz, 1H), 4.77-4.67 (m, 1H), 4.67-4.59 (m, 1H), 4.45-4.31 (m, 2H), 4.15-4.05 (m, 1H), 3.21-3.10 (m, 6H), 2.29-2.12 (m, 6H), 1.99-1.89 (m, 5H), 1.80-1.18 (m, 41H), 0.98-0.87 (m, 12H). ^{13}C NMR (100 MHz, CD_3OD): δ ppm 176.28, 176.04, 175.08, 174.93, 174.85, 173.83, 144.87, 123.67, 77.55, 53.28, 53.19, 51.97, 45.20, 43.79, 41.87, 41.79, 40.34, 40.29, 37.94, 37.07, 36.72, 33.81, 30.25, 30.19, 30.13, 27.67, 27.59, 26.74, 26.63, 25.93, 23.46, 23.39, 22.11, 22.01, 16.73. HRMS calcd. for $[\text{C}_{48}\text{H}_{81}\text{N}_6\text{O}_8]^+$ 869.61104, found 869.61133.




Boc-Leu₂-3-leucinylfuran-2(5H)-one (38). Following the general procedure for azide coupling the title compound was obtained from Boc-3-leucinylfuran-2(5H)-one **7** (71 mg, 264 μmol , 1.1 equiv.) and Boc-Leu₂-NHNH₂ **18** (86 mg, 240 μmol , 1 equiv). Purification by flash chromatography (EA:tol (30-70%)) gave the title compound (47 mg, 95 μmol , 40%). ^1H NMR (400 MHz, CDCl_3) δ ppm 7.38-7.35 (m, 1H), 7.01 (d, $J = 8.29$ Hz, 1H), 6.65 (d, $J = 7.30$ Hz, 1H), 5.11-5.02 (m, 1H), 4.94-4.82 (m, 1H), 4.82-4.75 (m, 2H), 4.43-4.34 (m, 1H), 4.11-4.02 (m, 1H), 1.75-1.40 (m, 18H), 1.02-0.80 (m, 18H). ^{13}C NMR (100 MHz, CDCl_3): δ ppm 172.73, 171.32, 156.10, 145.85, 134.29, 80.52, 70.24, 53.63, 52.19, 44.78, 41.65, 40.56, 28.21, 24.78, 22.93, 22.79, 21.76, 21.70, 21.54.

Cbz-Leu₂-3-leucinylfuran-2(5H)-one (VIIIa). Following the general procedure for azide coupling the title compound was obtained from Boc-3-leucinylfuran-2(5H)-one **7** (56 mg, 208 μmol , 1.1 equiv.) and Cbz-Leu₂-NHNH₂ **16** (79 mg, 200 μmol , 1 equiv). Purification by flash chromatography (EA:tol (20-50%)) gave the title compound **VIIIa** (91 mg, 172 μmol , 86%). α_D^{20} -76.8° ($c = 1.00$, CHCl_3). IR (film) 3346, 3329, 2957, 2870, 1738, 1697, 1672, 1647, 1541, 1506, 1456, 1387, 1367, 1269, 1209, 1070, 1040 cm^{-1} . ^1H NMR (400 MHz, $\text{CDCl}_3/\text{CD}_3\text{OD}$, 1/1): δ ppm 7.72 (d, $J = 8.27$ Hz, 1H), 7.43-7.28 (m, 6H), 5.11 (q, $J = 12.32, 12.28, 12.28$ Hz, 2H), 4.45-4.41 (m, 3H), 4.40-4.35 (m, 1H), 4.15 (dd, $J = 8.19, 6.69$ Hz, 1H), 1.75-1.43 (m, 9H), 1.02-0.82 (m, 18H). ^{13}C NMR (100 MHz, $\text{CDCl}_3/\text{CD}_3\text{OD}$, 1/1): δ ppm 173.37, 172.96, 171.98, 156.70, 146.27, 135.73, 134.03, 128.08, 127.75, 127.32, 70.26, 66.56, 53.65, 51.68, 44.31, 41.23, 40.55, 39.76, 24.38, 24.26, 22.41, 22.32, 22.28, 21.05, 20.96, 20.82. HRMS calcd for $[\text{C}_{29}\text{H}_{44}\text{N}_3\text{O}_6]^+$ 530.32246, found 530.32230.

Azido-Phe-Leu₂-3-leucinylfuran-2(5H)-one (VIIIb). Following the general procedure for block coupling, the title compound was obtained from Boc-Leu₂-3-leucinylfuran-2(5H)-one **38** (24.6 mg, 50 μmol , 1 equiv) and azido-phenylalanine **21** (12 mg, 64 μmol , 1.3 equiv.). Flash column chromatography (MeOH:DCM (0-2.5%)) yielded **VIIIb** (14 mg, 25 μmol , 50%). IR (film) 3277, 2957, 2932, 2110, 1749, 1639, 1541, 1457, 1387, 1340, 1287, 1207, 1067, 1049 cm^{-1} . ^1H NMR (400 MHz, CDCl_3) δ ppm 7.36-7.21 (m, 5H), 6.98 (d, $J = 8.58$ Hz, 1H), 6.80 (d, $J = 7.55$ Hz, 1H), 6.58 (d, $J = 7.89$ Hz, 1H), 4.90 (dd, $J = 15.58, 8.09$ Hz, 1H), 4.82-4.77 (m, 2H), 4.47-4.32 (m, 2H), 4.27 (dd, $J = 7.72, 4.09$ Hz, 1H), 3.29 (dd, $J = 14.09, 3.94$ Hz, 1H), 3.07 (dd, $J = 14.13, 7.76$ Hz, 1H), 1.80-1.20 (m, 9H), 0.95-0.81 (m, 18H). HRMS calcd for $[\text{C}_{30}\text{H}_{45}\text{N}_6\text{O}_5]^+$ 569.34459, found 569.34450.

Ada-Ahx₃-Leu₂- 3-leucinylfuran-2(5H)-one (VIIIc). Following the general procedure for block coupling, the title compound was obtained from Boc-Leu₂- 3-leucinylfuran-2(5H)-one **38** (23 mg, 46 μmol, 1 equiv.) and Ada-Ahx₃-OH **22** (27 mg, 51 μmol, 1.1 equiv.). Flash column chromatography (MeOH:DCM (3-8%)) yielded **VIIIc** (40 mg, 44 μmol, 95%). α_D^{20} -35.2° (c = 0.66, MeOH). IR (film) 3275, 2905, 1747, 1636, 1541, 1456, 1340, 1205, 1067, 1045 cm⁻¹. ¹H NMR (400 MHz, CD₃OD) δ ppm 8.23-8.07 (m, 4H), 7.97 (t, *J* = 4.76 Hz, 1H), 7.50-7.47 (m, 1H), 4.87-4.82 (m, 2H), 4.80-4.70 (m, 1H), 4.41-4.26 (m, 2H), 3.22-3.09 (m, 6H), 2.28 (t, *J* = 7.38 Hz, 2H), 2.20 (t, *J* = 7.32 Hz, 4H), 1.98-1.88 (m, 5H), 1.79-1.23 (m, 39H), 0.99-0.84 (m, 18H). ¹³C NMR (100 MHz, CD₃OD): δ ppm 176.67, 176.18, 176.15, 176.09, 175.25, 174.99, 174.27, 173.87, 149.49, 148.79, 135.42, 72.18, 53.92, 53.50, 51.94, 51.88, 49.86, 45.53, 43.71, 42.92, 41.60, 41.42, 40.32, 40.19, 40.13, 40.00, 37.86, 37.01, 36.70, 36.65, 33.79, 30.11, 30.01, 29.97, 27.51, 27.47, 27.32, 26.58, 26.51, 25.90, 25.88, 25.86, 23.59, 23.43, 23.41, 22.01, 21.90, 21.85. HRMS calcd for [C₅₁H₈₇N₆O₈]⁺ 911.65799, found 911.65872.




Boc-Leu₂-4-leuciny-furan-2(5H)-one (39). Following the general procedure for azide coupling the title compound was obtained from Boc-4-leuciny-furan-2(5H)-one **9** (124 mg, 0.46 mmol, 1.1 equiv.) and Boc-Leu₂-NHNH₂ **18** (149 mg, 0.42 mmol, 1 equiv). Purification by flash chromatography EA:tol (20-50%) gave the title compound (118 mg, 0.24 mmol, 57%). ¹H NMR (400 MHz, CDCl₃): δ ppm 6.62-6.58 (m, 1H), 5.92 (s, 1H), 5.13-5.08 (m, 1H), 4.96-4.74 (m, 3H), 4.58-4.50 (m, 1H), 4.03-3.95 (m, 1H), 1.70-1.40 (m, 18H), 1.05-0.96 (m, 18H).

Cbz-Leu₂-4-leuciny-furan-2(5H)-one (IXa). Following the general procedure for azide coupling the title compound was obtained from Boc-4-leuciny-furan-2(5H)-one **9** (77 mg, 286 μmol, 1.1 equiv.) and Cbz-Leu₂-NHNH₂ **16** (102 mg, 260 μmol, 1 equiv). Purification by flash chromatography (EA:tol (30-70%)) gave the title compound (112 mg, 211 μmol, 81%). α_D^{20} -80.2° (c = 1.00, CHCl₃). IR (film) 3269, 2957, 2934, 2870, 1782, 1751, 1699, 1668, 1641, 1539, 1471, 1456, 1387, 1369, 1261, 1238, 1153, 1120, 1030 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ ppm 7.41 (d, *J* = 8.16 Hz, 1H), 7.36-7.24 (m, 5H), 6.13 (d, *J* = 4.81 Hz, 1H), 5.92-5.89 (m, 1H), 5.15-4.97 (m, 2H), 4.88-4.66 (m, 3H), 4.43 (dd, *J* = 14.23, 7.30 Hz, 1H), 4.25-4.17 (m, 1H), 1.86-1.31 (m, 9H), 0.95-0.81 (m, 18H). ¹³C NMR (100 MHz, CDCl₃): δ ppm 173.74, 172.69, 172.05, 171.63, 156.78, 135.81, 128.53, 128.25, 127.59, 115.17, 71.61, 66.96, 54.24, 52.22, 45.81, 41.82, 41.07, 40.06, 24.92, 24.67, 24.44, 23.19, 22.69, 22.57, 21.96, 21.86, 21.16. HRMS calcd. for [C₂₉H₄₄N₃O₆]⁺ 530.32246, found 530.32224.

Azido-Phe-Leu₂-4-leuciny-furan-2(5H)-one (IXb). Following the general procedure for block coupling, the title compound was obtained from Boc-Leu₂-4-leuciny-furan-2(5H)-one **39** (59 mg, 120 μmol) and azido-phenylalanine **21** (26 mg, 130 μmol, 1.1 equiv.). Flash column chromatography (EA:tol (30-60%)) yielded **IXb** (31 mg, 55 μmol, 45%). α_D^{20} -61.6° (c = 0.38, CHCl₃). IR (film) 3273, 2957, 2932, 2872, 2110, 1782, 1753, 1638, 1541, 1465, 1437, 1387, 1369, 1248, 1223, 1153, 1032 cm⁻¹. ¹H NMR (400 MHz, CDCl₃): δ ppm 7.36-7.20 (m, 5H), 7.06-7.02 (m, 1H), 6.82-6.78 (m, 1H), 6.75-6.71 (m, 1H), 5.94-5.92 (m, 1H), 4.88-4.73 (m, 3H), 4.42-4.35 (m, 1H), 4.33-4.25 (m, 2H), 3.27 (dd, *J*₁ = 14.1 Hz, *J*₂ = 4.2 Hz, 1H), 3.08 (dd, *J*₁ = 14.1 Hz, *J*₂ = 7.5 Hz, 1H), 1.80-1.30 (m, 9H), 0.98-0.80 (m, 18H). ¹³C NMR (100 MHz, CDCl₃): δ ppm 171.77, 171.66, 171.11, 169.34, 135.41, 129.39, 128.71, 127.40, 115.44, 71.59, 64.91, 52.34, 52.07, 45.94, 42.02, 40.60, 39.97, 38.05, 24.95, 24.64,

24.59, 23.16, 22.76, 22.72, 21.90, 21.87, 21.34. HRMS: calcd. for $[C_{30}H_{45}N_6O_5]^+$ 569.34459, found 569.34443.

Ada-Ahx₃-Leu₂-4-leuciny-furan-2(5H)-one (IXc). Following the general procedure for block coupling, the title compound was obtained from Boc-Leu₂-4-leuciny-furan-2(5H)-one **39** (59 mg, 120 μ mol) and Ada-Ahx₃-OH **22** (69 mg, 130 μ mol, 1.1 equiv.). Flash column chromatography (MeOH:DCM (0-7%)) yielded **IXc** (87 mg, 96 μ mol, 80%). α_D^{20} -54.0° (c = 1.00, MeOH). IR (film) 3285, 2928, 2903, 2870, 1780, 1747, 1638, 1541, 1439, 1367, 1277, 1242, 1155, 1032 cm^{-1} . ¹H NMR (400 MHz, CD₃OD): δ ppm 7.85 (t, *J* = 5.2 Hz, 1H), 7.95 (t, *J* = 5.4 Hz, 2H), 5.95 (d, *J* = 1.5 Hz, 1H), 4.91-4.84 (m, 3H), 4.38-4.27 (m, 2H), 3.18-3.11 (m, 6H), 2.28-2.22 (m, 2H), 2.17 (t, *J* = 7.5 Hz, 4H), 1.96-1.92 (m, 3H), 1.92-1.90 (m, 2H), 1.83-1.44 (m, 33H), 1.39-1.29 (m, 6H), 0.98-0.88 (m, 18H). ¹³C NMR (100 MHz, CD₃OD): δ ppm 176.41, 175.95, 175.86, 175.06, 174.52, 174.27, 173.73, 115.72, 73.25, 53.65, 53.35, 51.94, 47.29, 43.75, 42.60, 41.62, 41.40, 40.31, 40.26, 40.18, 37.91, 37.04, 36.99, 36.62, 33.77, 30.22, 30.14, 27.65, 27.60, 27.56, 26.72, 26.54, 25.97, 25.90, 25.71, 23.70, 23.40, 22.11, 21.93, 21.49. HRMS: calcd. for $[C_{51}H_{87}N_6O_8]^+$ 911.65799, found 911.65874.



Cbz-Leu₂-(S,E)-5-amino-7-methyloct-2-en-4-one (Xa). Following the general procedure for azide coupling the title compound was obtained from (E,S)-1-isobutyl-2-oxo-pent-3-enyl-amine HCl salt **12** (38 mg, 200 μ mol, 1.1 equiv.) and Cbz-Leu₂-NHNH₂ **16** (71 mg, 180 μ mol, 1 equiv). Purification by flash chromatography (EA:tol (0-25%)) gave the title compound (62 mg, 120 μ mol, 67%). α_D^{20} -45.5° (c = 0.8, CHCl₃). IR (film) 3263, 2955, 2936, 2870, 1699, 1663, 1641, 1539, 1466, 1437, 1387, 1367, 1286, 1261, 1234, 1121, 1045, 1028, 970 cm^{-1} . ¹H NMR (400 MHz, CDCl₃): δ ppm 7.35-7.25 (m, 5H), 7.21 (d, *J* = 8.27 Hz, 1H), 6.20 (dd, *J* = 15.65, 1.56 Hz, 1H), 5.82 (d, *J* = 1.56 Hz, 1H), 5.16-5.01 (m, 2H), 4.88 (dt, *J* = 9.25, 9.17, 4.10 Hz, 1H), 4.59 (dd, *J* = 15.15, 7.54 Hz, 1H), 4.35-4.26 (m, 1H), 1.90 (dd, *J* = 6.86, 1.46 Hz, 3H), 1.76-1.35 (m, 9H), 0.94-0.82 (m, 18H), 7.06-6.95 (m, 1H). ¹³C NMR (100 MHz, CDCl₃): δ ppm 197.92, 172.09, 171.48, 156.19, 144.83, 136.34, 128.67, 128.40, 127.98, 127.84, 66.81, 54.21, 53.36, 51.66, 41.59, 41.19, 40.84, 24.78, 24.66, 24.57, 23.25, 22.72, 22.45, 22.19, 21.82, 18.41. HRMS calcd. for $[C_{29}H_{46}N_3O_5]^+$ 516.3432, found 516.34294.

Boc-Leu₂-(S,E)-5-amino-7-methyloct-2-en-4-one (40). Following the general procedure for azide coupling the title compound was obtained from (E,S)-1-isobutyl-2-oxo-pent-3-enyl-amine HCl salt **12** (100 mg, 520 μ mol, 1.1 equiv.) and Boc-Leu₂-NHNH₂ **18** (170 mg, 470 μ mol, 1 equiv). Purification by flash chromatography (EA:tol (0-25%)) gave the title compound (119 mg, 250 μ mol, 48%). ¹H NMR (400 MHz, CDCl₃): δ ppm 7.02 (dq, *J* = 15.51, 6.87 Hz, 1H), 6.85 (d, *J* = 7.39 Hz, 1H), 6.68 (d, *J* = 7.85 Hz, 1H), 6.21 (dd, *J* = 15.64, 1.66 Hz, 1H), 5.07 (d, *J* = 6.64 Hz, 1H), 4.89-4.82 (m, 1H), 4.54-4.45 (m, 1H), 4.17-4.07 (m, 1H), 1.93 (dd, *J* = 6.88, 1.60 Hz, 3H), 1.73-1.34 (m, 18H), 0.99-0.85 (m, 18H). ¹³C NMR (100 MHz, CDCl₃): δ ppm 197.79, 172.47, 171.49, 155.68, 144.85, 128.56, 54.37, 52.99, 51.65, 41.18, 40.97, 28.24, 24.80, 24.67, 24.58, 23.24, 22.80, 22.06, 21.85, 18.44.

Azido-Phe-Leu₃-(S,E)-5-amino-7-methyloct-2-en-4-one (Xb). Following the general procedure for block coupling, the title compound was obtained from Boc-Leu₂-(S,E)-5-amino-7-methyloct-2-en-4-one **40** (40 mg, 83 μ mol, 1 equiv) and azido-phenylalanine **21** (23 mg, 120 μ mol, 1.45 equiv.). Flash

column chromatography (MeOH:DCM (0-4%)) yielded **Xb** (36 mg, 66 μ mol, 79%). α_D^{20} -31.7° (c = 0.46, CHCl₃). IR (film) 3273, 2955, 2930, 2870, 2110, 1638, 1541, 1456, 1437, 1387, 1367, 1255, 1221, 1152, 970 cm⁻¹. ¹H NMR (400 MHz, CD₃OD): δ ppm 7.33-7.18 (m, 5H), 7.00 (dq, J = 20.73, 6.87 Hz, 1H), 6.28 (dd, J = 15.61, 1.66 Hz, 1H), 4.70 (dd, J = 9.12, 5.42 Hz, 1H), 4.47-4.41 (m, 1H), 4.14 (dd, J = 8.49, 5.00 Hz, 1H), 3.18 (dd, J = 14.03, 4.98 Hz, 1H), 2.97 (dd, J = 14.03, 8.51 Hz, 1H), 1.91 (dd, J = 6.87, 1.60 Hz, 3H), 1.74-1.45 (m, 9H), 1.00-0.85 (m, 18H). ¹³C NMR (100 MHz, CD₃OD): δ ppm 199.71, 174.31, 174.06, 145.97, 137.86, 130.44, 129.59, 129.37, 128.04, 65.49, 56.27, 53.10, 52.99, 42.06, 41.90, 40.91, 38.69, 25.97, 25.83, 23.68, 23.42, 23.33, 22.32, 22.14, 21.93, 18.54. HRMS calcd. for [C₃₀H₄₇N₆O₄]⁺ 555.36533, found 555.36519.

Ada-Ahx₃-Leu₂-(S,E)-5-amino-7-methyloct-2-en-4-one (Xc). Following the general procedure for block coupling, the title compound was obtained from Boc-Leu₂-(S,E)-5-amino-7-methyloct-2-en-4-one **40** (59 mg, 122 μ mol, 1 equiv.) and Ada-Ahx₃-OH **22** (72 mg, 135 μ mol, 1.1 equiv.). Flash column chromatography (MeOH:DCM (2-8%)) yielded **Xc** (88 mg, 98 μ mol, 80%). α_D^{20} -44.0° (c = 1.00, MeOH). IR (film) 3281, 2928, 2905, 2868, 1636, 1545, 1439, 1367, 1276, 1171, 1067, 972 cm⁻¹. ¹H NMR (400 MHz, CD₃OD): δ ppm 8.22 (d, J = 7.90 Hz, 1H), 8.08 (t, J = 6.69, 6.69 Hz, 2H), 7.95 (t, J = 5.01, 5.01 Hz, 2H), 7.88-7.82 (m, 1H), 7.04-6.94 (m, 1H), 6.32-6.26 (m, 1H), 4.68 (dd, J = 14.25, 8.13 Hz, 2H), 4.49-4.34 (m, 2H), 3.19-3.09 (m, 6H), 2.23 (t, J = 7.37, 7.37 Hz, 2H), 2.17 (t, J = 7.41, 7.41 Hz, 1H), 1.98-1.88 (m, 5H), 1.78-1.43 (m, 36H), 1.39-1.27 (m, 6H), 0.97-0.87 (m, 18H). ¹³C NMR (100 MHz, CD₃OD): δ ppm 199.63, 176.09, 175.95, 174.78, 174.46, 173.74, 145.86, 129.25, 56.38, 53.17, 52.99, 51.93, 43.74, 41.92, 41.85, 40.85, 40.31, 40.25, 37.90, 37.03, 36.98, 36.68, 33.76, 30.21, 30.13, 27.64, 27.56, 26.71, 26.61, 25.91, 25.78, 23.69, 23.45, 23.40, 22.22, 22.06, 21.90, 18.56. HRMS calcd. for [C₅₁H₈₉N₆O₇]⁺ 897.67873, found 897.67942.






Figure S1: Competition assay of indicated inhibitors at indicated final concentration in HEK293T cells, 37°C 1h, then MV151 (0.5 μ M final conc.) 1h, 37°C. Inhibitor **IIa** included as measure of no activity.



ii A.M.P. Koskinen, L. A. Otsomaa, *Tetrahedron*, **1997**, 53, 6473-6484

Compound 1



4.27
4.27
4.26
4.25
4.25
4.24
4.23
4.21
4.19
4.19

3.54
3.50

3.21

2.01
1.89
1.88
1.76
1.75
1.74
1.73
1.70
1.70
1.68
1.67
1.67
1.63
1.39
1.37
1.35

0.01
0.000

3.94

1.83

1.83



3.00

5.42

7.76

5.88

Compound 3



Compound 3

154.81

147.15

130.29

79.17

77.32

77.00

76.68

66.81

49.08

42.76

41.71

36.07

33.90

27.99


24.35

22.40

21.64

ppm (f1)

Compound 5



6.03
5.84
5.83

5.32
5.30
5.06

4.45
4.44
4.27
4.12
4.10
3.99
3.81
3.72

2.03
1.72
1.71
1.70
1.59
1.55
1.54
1.52
1.50
1.49
1.48
1.44
1.27
1.25
1.23
1.20
1.14
0.83

0.94


0.65

0.69



2.96
3.00


1.10
1.98
10.16

6.00




Compound 6





Compound 7



7.28 16.0 0.91



5.24 5.22 98.0 0.85

4.81 4.62 4.60 4.58 96.1 1.96 0.87



1.60 1.59 1.43 28.2 9.00

0.96 0.94 0.93 76.9 5.97



Compound 7




Compound 9




Compound 9






Compound 11



Compound 11



202.70



146.35



140.88



128.82



127.49



126.04



77.32



77.00



76.68



71.01



58.13



45.07



24.39



23.33



22.56





17.67




ppm (f1)

Compound 12



Compound 12



194.27

146.45

127.15

56.13

39.46



24.44


22.92

21.67



18.49

Compound 13






Compound 16



ppm (f1)

Compound 18



4.79
4.45
4.43
4.43
4.41
4.13
4.11
4.09

3.30

1.66
1.65
1.64
1.63
1.62
1.60
1.59
1.58
1.57
1.55
1.54
1.53
1.51
1.50
1.48
1.43
0.94
0.92
0.90
0.88

0.92



0.80

6.46


8.61

12.00

Compound 19





Compound 22




177.35
175.92
173.70




51.87
49.64
49.43
49.21
49.00
48.79
48.57
48.36
43.75
40.17
37.91
36.97
34.79
33.77
30.19
30.15
30.10
27.64

Compound 19





Compound 23



1.00

0.82

1.88



4.73

0.84




10.01

10.67


7.27



Compound 24



Compound 24




155.08
152.01
133.34
132.30
131.59
131.42
131.21
131.11
128.53
128.40
128.28
121.55
120.54

79.31
77.32
77.00
76.68


51.57
51.40

43.34
43.19

28.15
24.56
22.61
21.91



Compound 25



4.31
4.29
4.27
4.25
4.24

3.51
3.46

2.21
2.05
2.04
1.78
1.75
1.72
1.68
1.40
1.38
1.36

3.97

2.04



3.07

6.05


6.20

6.00

Compound 25



Compound 26



6.71
6.70
6.68
6.66
6.35
6.31

5.18
5.16

4.35
4.34

2.14
1.97
1.75
1.72
1.70
1.67
1.45
1.44
0.95
0.95
0.94
0.93

0.84

0.87

0.71

0.82

2.70


5.23

6.43

11.06

6.00

Compound 26



154.76
150.74

122.69

79.15
77.32
77.00
76.68

59.98
59.38

49.74

42.37

37.53

35.43

34.20

27.96



27.74


24.33

22.32

21.72

Compound 27





Compound 27

173.95
170.82

77.32
77.00
76.68

51.78
51.42

42.57

39.01

36.70


33.80

32.62


29.33

28.57

26.36



Compound 28



177.96

171.56

77.32

77.00

76.68

51.50

42.49

39.16

36.63

33.87


32.64

29.12


28.51

26.25

ppm (f1)





Compound 29





77.32
77.00
76.68

51.55
51.38
42.53
39.08
39.00
36.66
36.28
33.75
32.58
29.28
29.15
28.51
26.41
26.38

Compound 30





Compound 30



ppm (f1)

Compound 32








Compound 32

ppm (f1)



Compound 33





Compound 33




Compound 35






Compound 37




Compound 37



Compound 38










Compound 38



Compound 39





9.86

4.69



1.69

18.00




Compound Ia





Compound Ia




Compound Ib





Compound Ib








ppm (f1)

Compound 1c



Compound IIa



1.78

5.35

1.84

0.97

1.93

1.86

0.88

3.92


0.87


7.05

7.30



18.00

Compound IIa








Compound IIc




Compound IIc







ppm (f1)


Compound IIIa





Compound IIIb




Compound IIIb



Compound IIIc



Compound IVb



0.88
9.71

0.94

0.91

1.00
1.74


0.84

0.83
0.88



3.46
5.92

9.65
5.70


18.00



Compound IVb



Compound IVc



0.43
1.35
0.68

0.87

0.86

0.86

0.83
0.91

6.00

2.29
7.14

11.05

40.44

6.57

16.70

8.06
8.04
8.03
8.01
7.93
7.91
7.90
7.81

6.71
6.70
6.67
6.66
6.43
6.39

4.65
4.64
4.63
4.36
4.34
4.33
4.26
4.24
4.23
4.22



3.12
3.11



2.24
2.23
2.21

2.16
2.14
2.12
2.09







1.93
1.88
1.75
1.72
1.69
1.61
1.59
1.53
1.51
1.49
1.47
1.46
1.44
1.31
1.29

Compound IVc





Compound Vc



1.88
1.05
2.12

1.05
1.05

1.19
2.21



7.12
2.00


2.46
4.91
9.93
7.52
47.71

8.16

21.35


Compound Vc







ppm (f1)

Compound VIa









Compound VIb




Compound VIC




Compound VIc






Compound VIIa



Compound VIIa



172.37

143.01

128.56

128.33

128.18

123.16

77.00

75.96

67.58

54.37

52.21

43.74

40.66

31.41

24.98

24.88

24.82



22.87

21.73

21.50

16.22

Compound VIIb



7.31
7.30
7.28
7.27
7.26
7.24
7.23
6.94
6.92
6.91
6.90

6.16
6.13

4.73
4.73
4.72
4.71
4.64
4.63
4.62
4.61

4.42
4.40
4.39
4.38
4.36

4.17
4.16
4.15
4.14

3.31
3.22
3.20

3.18
3.17
3.01

2.98
2.97
2.95


1.69
1.69
1.67
1.66
1.64
1.64

1.62
1.61
1.60

1.59
1.55
1.54

1.53
1.52
1.30
1.29
0.91

Compound VIIb



174.20

144.86

130.49

129.58

128.04

123.71

77.59

65.55

53.26

45.21

41.91

41.79

38.71

25.94

25.83

23.43



23.36

22.13





22.05

16.73

Compound VIIf



Compound VIIIa



0.93

5.85

1.95

9.8


1.00

8.98

18.00



Compound VIIIb



6.71

0.70

0.75

0.85

1.71
0.89


0.85
1.98

0.88


0.87

11.24

18.00



Compound VIIIc



8.21
8.19
8.17
8.15
8.13
8.11
7.98
7.97
7.49


5.49


4.85
4.77
4.76
4.75
4.39
4.37
4.36
4.34
4.32
4.30
4.28

3.17
3.16




0.67
0.95
0.93
0.92
0.90
0.88

3.41
0.68
0.81
2.02
0.90
1.93
6.00
3.97
5.13
33.54
8.23
17.39







Compound IXa



Compound IXb



171.79
171.68
171.14
169.37


135.43
129.41
128.74
127.42

115.47

77.02
71.62
64.93



52.36
52.09
45.96
42.05
40.63
40.00
38.08
24.97
24.73
24.67
24.62
23.18
22.79
22.75
21.62

Compound IXb





ppm (f1)

Compound IXc




Compound IXc




ppm (f1)


Compound Xa



4.99 0.81 1.83 0.94 0.92 1.92 0.92 0.91 0.85 2.77 9.35 18.00



Compound Xa



197.94

172.11

171.50

156.21

144.85

136.36

128.69

128.42

128.00

127.86

66.83

54.23

53.38

51.68

41.61

41.21

40.86

24.80

24.68

24.59

23.27


22.74

22.47

22.21

ppm (f1)

Compound Xb



199.71

174.32

174.06

171.49

145.98

137.86

130.44

129.60

129.37

128.04

65.49

56.28

53.11

52.99

42.06

41.90

40.91

38.69

25.98

25.83

23.68

23.42

23.33

22.33

22.15

ppm (f1)

